Pulsatile Drug-Delivery Systems

Bussemer, Till; Otto, Ina; Bodmeier, Roland

doi:10.1615/critrevtherdrugcarriersyst.v18.i5.10

Cited by 155 publications

(100 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The drugs used in the treatment of IBD, ulcerative colitis, diarrhea and colon cancer are ideal candidates for local colon delivery [10]. Criteria for selection drugs for CDDS are summarized in table 2.…”

Section: Drug Candidatementioning

confidence: 99%

See 1 more Smart Citation

Primary and novel approaches for colon targeted drug delivery – A review

Tiwari¹,

Tiwari²,

Wal³

et al. 2010

Int. J. Drug Delivery

View full text Add to dashboard Cite

The colon is a site where both local and systemic delivery of drugs can take place. Local delivery could, for example, allow topical treatment of inflammatory bowel disease. Treatment could be made more effective if it were possible for drugs to be targeted directly on the colon. Systemic side effects could also be reduced. Colon specific systems might also allow oral administration of peptide and protein drugs, which are normally inactivated in the upper parts of the gastrointestinal tract. Primary approaches for CDDS (Colon Specific Drug Delivery), which includes prodrugs, pH and time dependent systems and microbially triggered drug delivery system achieved limited success and having limitations. Newly developed CDDS, which includes pressure controlled colonic delivery capsules (PCDCS), CODES TM and osmotic controlled drug delivery are unique in terms of achieving in vivo site specificity and feasibility of manufacturing process. This review also focuses on evaluations of CDDS in general.

show abstract

Section: Drug Candidatementioning

confidence: 99%

“…[A]-Primary approaches for CDDS [10] a -pH sensitive polymer coated drug delivery to colon b -Delayed (Time controlled release system) release drug delivery to colon c -Microbially triggered drug delivery to colon (i) Prodrug approach for drug delivery to colon…”

Section: Drug Carriermentioning

confidence: 99%

Primary and novel approaches for colon targeted drug delivery – A review

Tiwari¹,

Tiwari²,

Wal³

et al. 2010

Int. J. Drug Delivery

View full text Add to dashboard Cite

show abstract

“…In other words, it is required that the drug should not be released at all during the initial phase of dosage form administration. Such a release pattern is known as pulsatile release [2]. Recent studies have revealed that diseases have a predictable cyclic rhythm and doi:10.5138/ijdd.2010.0975.0215.02030 ©arjournals.org, All rights reserved.…”

Section: Introductionmentioning

confidence: 99%

“…that the timing of medication regimens can improve the outcome of a desired effect [2]. This condition demands release of drug as a "pulse" after a time lag and such system has to be designed in a way that complete and rapid drug release should follow the lag time.…”

Section: Introductionmentioning

confidence: 99%

Recent trends in pulsatile drug delivery systems - A review.

Sharma¹,

Srikanth²,

Uhumwangho³

et al. 2010

Int j Drug delivery

View full text Add to dashboard Cite

The purpose of writing this review on pulsatile drug delivery systems (PDDS) is to compile the recent literatures with special focus on the different types and approaches involved in the development of the formulation. PDDS are gaining importance in the field of pharmaceutical technology as these systems deliver the right dose at specific time at a specific site. Some of the disease conditions wherein PDDS are promising include duodenal ulcer, cardiovascular diseases, arthritis, asthma, diabetes, neurological disorder, cancer, hypertension and hypercholesterolemia. PDDS can be classified into time controlled systems wherein the drug release is controlled primarily by the delivery system, stimuli induced PDDS in which release is controlled by the stimuli, such as the pH or enzymes present in the intestinal tract or enzymes present in the drug delivery system and externally regulated system where release is programmed by external stimuli like magnetism, ultrasound, electrical effect and irradiation. This review also summarizes some current PDDS already available in the market. These systems are useful to several problems encountered during the development of a pharmaceutical dosage form.

show abstract

“…Keywords: felodipine, b-cyclodextrin, chronotherapeutic, ethyl cellulose pressure, hormonal levels) and pathophysiological disease states (e.g., hypertension, myocardial infarction, bronchial asthma and rheumatic disease) show a circadian pattern in their manifestations (2,3). Therefore, the management of such disease states should preferentially involve delivery systems that release drugs after a specified delay period (lag period-time of no drug release) after dosing (4).…”

mentioning

confidence: 99%

Felodipine β-cyclodextrin complex as an active core for time delayed chronotherapeutic treatment of hypertension

Pagar

Vavia²

2012

Acta Pharmaceutica

View full text Add to dashboard Cite

The key to the success of any drug delivery system depends upon the development of formulations that accomplish the therapeutic needs associated with a particular pathological condition or disease state (1). Many physiological body functions (e.g., blood The present research work deals with the development of a time delayed chronotherapeutic formulation of felodipine (FD) aimed at rapid drug release after a desired lag time in the management of hypertension. The developed system comprises a drug core embedded within a swellable layer and coated with an insoluble, water permeable polymeric system. FD cyclodextrin complex was used as an active core while ethyl cellulose was used as an effective coating layer. Dissolution studies of the complex revealed that there was a 3-fold increase in dissolution of the complex compared to plain FD. This dissolution enhancement and rapid drug release resulted from FD amorphisation, as confirmed by XRD, DSC and SEM studies. FTIR and 1 H NMR studies confirmed the complex formation between FD and cyclodextrin based on the observed hydrogen bond interactions. FD release was adequately adjusted by using a pH independent polymer, i.e., ethyl cellulose, along with dibutyl phthalate as plasticizer. Influence of formulation variables like polymer viscosity, plasticizer concentration, super disintegrant concentration in the swellable layer and percent coating weight gain was investigated to characterize the lag time. Upon permeation of water, the core tablet swelled, resulting in the rupture of the coating layer, followed by rapid drug release. The developed formulation of FD showed a lag time of 5-7 h, which is desirable for chronotherapeutic application.

show abstract

Pulsatile Drug-Delivery Systems

Cited by 155 publications

References 0 publications

Primary and novel approaches for colon targeted drug delivery – A review

Primary and novel approaches for colon targeted drug delivery – A review

Recent trends in pulsatile drug delivery systems - A review.

Felodipine β-cyclodextrin complex as an active core for time delayed chronotherapeutic treatment of hypertension

Contact Info

Product

Resources

About